Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLR-101 is an engineered yeast strain developed as a live biotherapeutic product. Its primary function is to produce enzymes that locally degrade specific antibiotics in the gut, thereby managing and mitigating the impact of antibiotics on the gut microbiome. This approach aims to protect beneficial gut bacteria during antibiotic therapy by breaking down residual antibiotics before they can disrupt the microbial community. The drug represents a novel strategy for preserving microbiome health during or after antibiotic use[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FLR-101.